The Role of 5-Aza-CdR on Methylation of Promoter in RASSF1A Gene in Endometrial Carcinoma

HUANG Li-ping, CHEN Chen, WANG Xue-ping. et al

Abstract

To explore the effect of demethylating drug 5-Aza-2′-deoxycytidine (5-Aza-CdR) on methtylation status of the Ras-association domain family1A gene (RASSF1A) in human endometrial carcinoma. Methods Randomly assign the human endometrial carcinoma cell line HEC-1-B into groups and use demethylating drug 5-Aza-CdR of different concentration to treat them. Then Methylation-specific polymerase chain reaction (MSP), real-time PCR, Western blot, TUNEL technology were used to analyze methylation status of RASSF1A promoter CpG islands,RASSF1A mRNA expression, RASSF1A protein expression and apoptosis of HEC-1-B cell. Results High DNA methylation in RASSF1A gene promoter region, low RASSF1A mRNA level and protein expression and out of control of human endometrial carcinoma cell HEC-1-B apoptosis were observed. 5-Aza-CdR of different concentration could reverse RASSF1A gene’s methylation status, recover the expression of mRNA and protein, and control the growth of HEC-1-B by inducing apoptosis. Conclusion Aberrant methylation of RASSF1A in endometrial cancer as a therapeutic target, demethylating agent 5-Aza-CdR could be an effective way of gene therapy.

 

Keywords: RASSF1A gene, Methylation, Endometrial cancer 

 

Full Text:

PDF


References


Dammann R, Li С, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour

suppressor locus 3p21. 3. Nat Genet, 2000 ;25( 3); 315-319. Richter AM. Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009; 1796 ( 2 ): 114- 128.

Ha YS. Jeong P. Kim JS. et al. Tumorigenic and prognostic significance of RASSF 1A expression in low-grade (WHO Grade 1 and Grade 2) nonmuscle-invasive bladder cancer. Urology. 2012;79(6): 1411-1416.

Hu L. Chen G. Yu HP. et al. Clinicopathological significance of RASS1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int.2010;4( 1):423-432.

Hagrass HA, Pasha HF, Shaheen MA, et al. Methylation status and protein expression of RASSF1A in breast cancer patients. Mol Biol Rep.2014 ;41 (1);57-65.

Nilsson TK. Lof-Ohlin ZM. Sun XF. DNA methylation of the pl4(ARF), RASSFlЛ and APC1A genes as an independent prognostic factor in colorectal cancer patients. Int J Oncol, 2013;4 2(1)j127-133.

Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature, 2004; 429 (6990);457-463.

Zhang YQ, Mao XY. Methylation of promoter in RASSFIA gene and its mRNA expression in human endometrial carcinoma cell line HEC-l-B. Med J Co,2010;24(1): 10-12.

Yamaguchi S, Asanoma К. Takao T, et al. Homeobox gene HOPX is epigenetically silenced in human uterine endometrial cancer and suppresses estrogen-stimulated proliferation of cancer cells by inhibiting serum response factor. Int J Cancer, 2009;124(11):2577-2588.

Ignatov A, Bischoff J, Schwarzenau C, et al. P16 alterations increase the metastatic potential of endometrial carcinoma. Gynecol Oncol,2008; 111 (2);365-371.

Arafa M, Kridelka F, Mathias V. et al. High frequency of RASSFIA and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology,2008;53(5) ;525-532.

Fiegl H, Oattringer C, Widschwendter A, et al. Methylated DNA collected by tampons a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev, 2004; 13 (5) ; 882- 888.

Jo H, Kim JW, Kang GH. et al. Association of promoter hypermethylation of the RASSFIA gene with prognostic parameters in endometrial cancer. Oncol Res,2006; 16(4); 205- 209.


Refbacks

  • There are currently no refbacks.